Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04551430 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
A Phase 2 study of Metastatic Soft Tissue Sarcoma, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 4
- Study locations
NCT04551430 is a Phase 2 study of Metastatic Soft Tissue Sarcoma that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 105 participants, below the 131-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (20% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04551430, a Phase 2 study of Metastatic Soft Tissue Sarcoma, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 4
- Study locations
Study Summary
The hypothesis of this study is that the response rate of soft tissue sarcoma will be improved with the addition of PD-1 and CTLA-4 inhibition to cabozantinib, and that cabozantinib priming will increase the response to nivolumab and ipilimumab.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Cabozantinib
Study Locations (4)
California
- Stanford University Medical Center - Stanford
Colorado
- University of Colorado - Aurora
Missouri
- Washington University School of Medicine - St Louis
Pennsylvania
- Abramson Cancer Center at Pennsylvania Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2021-01-05 |
| Est. Completion | 2029-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04551430
The ClinicalTrials.gov registry entry for NCT04551430 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (20% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Soft Tissue Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT04551430 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Missouri.
Frequently Asked Questions
What is clinical trial NCT04551430 about?
NCT04551430 is a clinical study titled "Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma". The hypothesis of this study is that the response rate of soft tissue sarcoma will be improved with the addition of PD-1 and CTLA-4 inhibition to cabozantinib, and that cabozantinib priming will increase the response to nivolumab and ipilimumab.
What is the current status of trial NCT04551430?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2021-01-05. Estimated completion is 2029-02-01.
What conditions does trial NCT04551430 study?
This clinical trial studies the following conditions: Metastatic Soft Tissue Sarcoma.
What interventions are being tested in trial NCT04551430?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT04551430?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04551430 being conducted?
This trial has 4 study locations across California, Colorado, Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
RECRUITING · Phase 2
-
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
COMPLETED · Phase 2
-
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
RECRUITING · Phase 1
-
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.